The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities
Journal of Respiration · 2021
DOI: 10.3390/jor1010005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Respiration, 2021. Verfasst von Selvakumar Subbian. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Covid Research and Pandemic Preparedness of the Rutgers University.
Abstract (Originalsprache)
The Coronavirus Disease-2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has claimed 1.2 million people globally since December 2019. Although the host factors underpinning COVID-19 pathology are not fully understood, type I interferon (IFN-I) response is considered crucial for SARS-CoV-2 pathogenesis. Perturbations in IFN-I signaling and associated interferon-inducible genes (ISG) are among the primary disease severity indicators in COVID-19. Consequently, IFN-I therapy, either alone or in- combination with existing antiviral or anti-inflammatory drugs, is tested in many ongoing clinical trials to reduce COVID-19 mortality. Since signaling by the IFN-I family of molecules regulates host immune response to other infectious and non-infectious diseases, any imbalance in this family of cytokines would impact the clinical outcome of COVID-19, as well as other co-existing diseases. Therefore, it is imperative to evaluate the beneficial-versus-detrimental effects of IFN-I immunotherapy for COVID-19 patients with divergent disease severity and other co-existing conditions. This review article summarizes the role of IFN-I signaling in infectious and non-infectious diseases of humans. It highlights the precautionary measures to be considered before administering IFN-I to COVID-19 patients having other co-existing disorders. Finally, suggestions are proposed to improve IFN-I immunotherapy to COVID-19.
Förderung
- Center for Covid Research and Pandemic Preparedness of the Rutgers University
Zitieren
APA
Subbian, S. (2021). The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities. Journal of Respiration. https://doi.org/10.3390/jor1010005
Vancouver
Subbian S. The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities. Journal of Respiration. 2021. doi:10.3390/jor1010005
BibTeX
@article{Subbian2021,
author = {Subbian, Selvakumar},
title = {The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities},
journal = {Journal of Respiration},
year = {2021},
doi = {10.3390/jor1010005}
}
EUVIMED